Cure My Disease

Don't miss your cure!

 Log in / Sign up

Large UK study tracks COVID-19's toll on MS patients

NCT ID NCT04354519

Knowledge-focused Sponsor: Swansea University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study follows thousands of people with multiple sclerosis (MS) in the UK to see how COVID-19 affects them. Researchers track infections, hospital stays, and deaths using questionnaires and national health data. The goal is to understand the risks and outcomes for this group, helping doctors and patients make informed decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how COVID-19 affects people with MS, guiding better care and public health advice.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply outside the UK.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,000 people

The number who actually took part.

Started

Mar 2020

Finished

Jul 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

PwMS in the UK who self report as having MS, or have been recruited at a clinical site. Given the potentially vulnerable nature of pwMS due to active drug treatment and their potential susceptibility to infection it is important to chart this population within the MS Register

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>18 and confirmed diagnosis of MS, enrolled on UK MS Register Exclusion Criteria: * None of the above

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Multiple sclerosis

Contacts and locations

Locations

  • Swansea Univeristy

    Swansea, SA28PP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.